Tag Archives: Lung

Vaping and waterpipes ‘multiply risks of developing lung diseases’

Both smoking and vaping can stiffen the arteries and increase the risk of developing adverse lung conditions, scientists have said. Their findings are based on a clinical review of the available evidence gathered from multiple studies. An analysis by an international team of researchers found that tobacco cigarettes, in general, were more harmful than electronic… Read More »

How some of the sickest COVID-19 patients are being saved by an out-of-body lung experience

Ventilators have failed to help and death looks imminent, but for some of Canada’s sickest COVID-19 patients, there is another, out of-body option. Several were recently connected to what amounts to an artificial lung sitting next to their beds, technology that has saved at least two people so far. The extra-corporeal membrane oxygenation (ECMO) machines… Read More »

FDA Approves Ofev (Nintedanib), For The Treatment of Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype

FDA Approves Ofev (Nintedanib), For The Treatment of Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype Print this page March 09, 2020 — The U.S. Food and Drug Administration today approved Ofev (nintedanib) oral capsules to treat patients with chronic fibrosing (scarring) interstitial lung diseases (ILD) with a progressive phenotype (trait). It is the… Read More »

FDA Approves Genentech’s Tecentriq Plus Chemotherapy (Abraxane and Carboplatin) for The Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer

Print this page South San Francisco, CA — December 3, 2019 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq (atezolizumab) in combination with chemotherapy (Abraxane ® [paclitaxel protein-bound; nab-paclitaxel] and carboplatin) for the initial (first-line) treatment of adults… Read More »

Asthma with lung capacity

Hypoxia and Hypoxemia What’s the difference? Depending on the disease, vital capacity will be impacted differently. This is used to collect data on traffic to articles and other pages on our site. CART and SLOW patients both improved, but CART benefits were long-lasting Patients in the study were from the Dallas-Fort Worth area, all of… Read More »

Takeda eyes Alunbrig earlier lung cancer use as 2-year data trounce Pfizer’s Xalkori

Pfizer’s aging Xalkori is the drug to beat in ALK-positive non-small cell lung cancer arena. And that’s just the arena Takeda is aiming for with earlier use of its own treatment Alunbrig. After 25 months of treatment, Alunbrig cut the risk of disease progression by 51% compared with Xalkori in ALK inhibitor-naïve NSCLC, as assessed by… Read More »

Chemo-Loaded Nanoparticles Piggyback on Red Blood Cells to Treat Lung Cancer

Scientists at Harvard’s Wyss Institute have developed a technique to deliver chemotherapy to the lungs using red blood cells. The method involves binding chemotherapy-loaded nanoparticles to red blood cells, which are then injected into the bloodstream. Once the red blood cells reach the lungs they have to squeeze through the small capillaries and the resulting… Read More »